What are Rigel Pharmaceuticals's total assets?

Rigel Pharmaceuticals (RIGL) holds $504.6M in total assets, up 186.8% year over year.

How much debt does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals carries $68.4M in total debt against $399.9M of shareholders' equity, a debt-to-equity ratio of 0.17.

How much cash does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals holds $24.5M in cash and equivalents.

Can Rigel Pharmaceuticals cover its short-term obligations?

Its current ratio is 2.62 — current assets exceed current liabilities.

Where does Rigel Pharmaceuticals's balance sheet data come from?

Every line is extracted from Rigel Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Rigel Pharmaceuticals RIGL Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$40.64M-28.4%	$56.75M+73.1%	$32.79M+34.0%	$24.46M+29.5%
Short-term investments	$114.38M+456%	$20.58M-14.8%	$24.15M-28.4%	$33.75M-68.2%
Restricted cash	$57K—	$0—	——	——
Accounts receivable, net	$51.76M+24.4%	$41.62M+36.2%	$30.55M-24.2%	$40.32M+161%
Inventories	$11.51M+91.7%	$6M+8.7%	$5.52M-39.4%	$9.12M+37.8%
Raw materials	$4.51M+319%	$1.08M—	——	——
Work in process	$3.91M+219%	$1.23M—	——	——
Finished goods	$4.71M-6.0%	$5.01M—	——	——
Prepaid expenses and other current assets	$21.94M+116%	$10.17M+62.4%	$6.26M-24.2%	$8.26M+11.4%
Accrued investment income	$900K—	——	——	——
Total current assets	$240.17M+77.8%	$135.1M+36.1%	$99.27M-14.4%	$115.9M-25.0%
Operating lease right-of-use assets	$920K+274%	$246K-71.4%	$861K-55.4%	$1.93M-80.1%
Goodwill	$24.75M-8.7%	$27.1M+95.3%	$13.88M-7.2%	$14.95M—
Intangible assets, net	$24.75M-8.7%	$27.1M—	——	——
Deferred tax assets	$245.85M+10.4%	$222.74M—	——	——
Other non-current assets	$1.91M+25.0%	$1.53M-50.0%	$3.06M+377%	$640K-34.3%
Total investment securities	$134.94M+136%	$57.19M—	——	——
Available-for-sale securities	$120.25M+195%	$40.79M—	——	——
Accumulated depreciation	$317K+21.5%	$261K—	——	——
Total assets	$513.59M+213%	$163.98M+39.9%	$117.23M-12.7%	$134.28M-19.8%
Accounts payable	$7.19M+115%	$3.34M-53.2%	$7.14M-68.3%	$22.51M+493%
Accrued expenses	$11.91M+17.5%	$10.14M+16.9%	$8.68M-2.1%	$8.87M-17.1%
Current portion of long-term debt	$30M—	——	——	——
Operating lease liabilities, current	$614K+115%	$285K-58.8%	$692K-38.9%	$1.13M-88.5%
Total current liabilities	$99.24M+56.8%	$63.3M+18.8%	$53.27M-18.3%	$65.21M+2.6%
Deferred tax liabilities	$327K+436%	$61K—	——	——
Long-term debt	$52.5M—	——	——	——
Operating lease liabilities, non-current	$395K—	$0-100%	$285K-70.7%	$972K+28.1%
Total liabilities	$122.11M-24.0%	$160.69M+10.2%	$145.87M-1.4%	$147.9M+8.0%
Common stock	$18K-100.0%	$400M+2,352,841%	$17K-90.2%	$174K+1.2%
Additional paid-in capital	$1.41B+1.5%	$1.39B+1.0%	$1.38B+0.7%	$1.37B+1.1%
Retained earnings	-$1.02B+26.4%	-$1.39B+1.2%	-$1.41B-1.8%	-$1.38B-4.4%
Accumulated other comprehensive income (loss)	$181K+1,710%	$10K+25.0%	$8K+105%	-$153K-50.0%
Total stockholders' equity	$391.48M+11,806%	$3.29M+111%	-$28.64M-110%	-$13.62M-145%
Total liabilities and stockholders' equity	$513.59M+213%	$163.98M+39.9%	$117.23M-12.7%	$134.28M-19.8%
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	9—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$7.96M—	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	$7.96M—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$7.96M—	——	——	——
Cash, Cash Equivalents, and Marketable Securities	$120.43M+195%	$40.8M—	——	——
Cash Cash Equivalents And Short Term Investments	$155.01M+100%	$77.32M—	——	——
Other current assets	$5.21M+15.1%	$4.52M—	——	——
Deferred Tax Assets and Other Non-Current Assets	$3.3M+19.8%	$2.75M-10.0%	$3.06M+377%	$640K-34.3%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	$2.35M—	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)	$12.99M—	——	——	——
Finite Lived Intangible Assets - Gross	$30.36M0.0%	$30.36M—	——	——
Goodwill and Intangible Assets, Net	$24.75M-8.7%	$27.1M+95.3%	$13.88M-7.2%	$14.95M—
Net Investment in Lease	$920K+274%	$246K-71.4%	$861K-55.4%	$1.93M-80.1%
Deferred tax assets	$245.85M—	$0—	——	——
Intangible assets — net	$24.75M-8.7%	$27.1M—	——	——
Goodwill and intangible assets, net	$24.75M-8.7%	$27.1M+95.3%	$13.88M-7.2%	$14.95M—
Operating lease right-of-use assets	$920K+274%	$246K-71.4%	$861K-55.4%	$1.93M-80.1%
Other non-current assets	$1.91M+25.0%	$1.53M-50.0%	$3.06M+377%	$640K-34.3%
Property, plant and equipment at cost	$347K-1.7%	$353K—	——	——
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$114.38M+456%	$20.58M-14.8%	$24.15M-28.4%	$33.75M-68.2%
Operating Lease Right-of-Use Assets in Other Assets	$920K+274%	$246K-71.4%	$861K-55.4%	$1.93M-80.1%
Software and Technology Licenses, Net	$1.91M+25.0%	$1.53M-50.0%	$3.06M+377%	$640K-34.3%
Tax Credit Carryforward Valuation Allowance	$46.7M-85.8%	$329.23M—	——	——
Accrued Manufacturing Costs	$11.91M+17.5%	$10.14M+16.9%	$8.68M-2.1%	$8.87M-17.1%
Accrued Rebates, Returns, and Promotions	$27.72M+4.8%	$26.44M+68.6%	$15.68M+29.1%	$12.15M+53.4%
Accrued research and development	$5.52M+35.6%	$4.07M+15.9%	$3.51M-54.4%	$7.71M-25.8%
Compensation and benefits	$11.91M+17.5%	$10.14M+16.9%	$8.68M-2.1%	$8.87M-17.1%
Current portion of mortgage and loans payable	$29.81M+310%	$7.27M+0.6%	$7.23M—	——
Operating Lease Liability Payments - 2024 (Lessee)	$409K—	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	$409K—	——	——	——
Lease Liability Payments - Due Year Two	$409K—	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	$692K—	——	——	——
Operating Lease Liability Payments Due	$1.1M—	——	——	——
Debt Maturity - 2024	——	——	——	——
Debt Maturity - 2027	$22.5M—	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$206K-35.6%	$320K—	——	——
Operating Lease Liability Payments - 2026 (Lessee)	$409K—	——	——	——
Total debt	$83.51M+29,201%	$285K-70.8%	$977K-53.6%	$2.11M-80.3%
Total Carrying Value of Debt	$52.5M-12.5%	$60M—	——	——
Unrecognized Tax Benefits	$9.05M+3.1%	$8.78M+1.2%	$8.67M-8.0%	$9.43M—
Unrecognized Tax Benefits - Income Tax Penalties and Interest Accrued	$0—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.00—	——	——
Common Stock Shares Issued	18.3M+3.4%	17.7M—	——	——
Convertible Preferred Stock Authorized Shares	10M0.0%	10M—	——	——
Convertible Preferred Stock Issued Shares	0—	0—	——	——
Convertible Preferred Stock Outstanding Shares	0—	0—	——	——
Additional paid-in capital	$1.41B+1.5%	$1.39B+1.0%	$1.38B+0.7%	$1.37B+1.1%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$18K0.0%	$18K+5.9%	$17K-90.2%	$174K+1.2%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.00—	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	$14.7M—	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	——	——	——	——
Unrealized Gains on Investments	$184K+1,740%	$10K—	——	——
Unrealized Losses on Investments (Before Tax)	$3K—	$0—	——	——
Cumulative Cost Basis	$347K-1.7%	$353K—	——	——
Accrued commercial expenses	$2.19M-40.1%	$3.66M—	——	——
Accrued other expenses	$7.92M+17.6%	$6.74M—	——	——
Contingent liabilities	$5M—	$0—	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$3K—	$0—	——	——
Gross Unrealized Gains	$184K+1,740%	$10K—	——	——
Available for sale investments	$120.43M+195%	$40.8M—	——	——
Common stock, par value (in dollars per share)	$00.0%	$0—	——	——
Common stock, shares authorized (in shares)	$400M0.0%	$400M—	——	——
Common stock, shares issued (in shares)	$18.31M+3.4%	$17.71M—	——	——
Common Stock, Shares, Outstanding	$18.31M+3.4%	$17.71M—	——	——
Customer refunds and credits	$27.72M+4.8%	$26.44M+68.6%	$15.68M+29.1%	$12.15M+53.4%
Customer Allowance For Prompt Payment Discounts	$338K+37.4%	$246K+36.7%	$180K+32.4%	$136K—
Long-term debt, gross	$52.5M-12.5%	$60M—	——	——
Debt Principal Outstanding, Net Of Unamortized Debt Issuance Costs	$52.29M-12.4%	$59.68M—	——	——
Fixed maturities, allowance for credit loss, current	$0—	$0—	——	——
Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss	$120.25M+195%	$40.79M—	——	——
Less than 12 months	$7.96M—	——	——	——
Number of Securities, Greater than 12 months	$9—	——	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$3K—	——	——	——
Capitalized research and development expenses	$5.17M-73.7%	$19.6M—	——	——
Deferred Tax Assets, Gross	$292.55M-11.1%	$329.23M—	——	——
Deferred Tax Assets, Net of Valuation Allowance	$245.85M—	$0—	——	——
Deferred Tax Assets, Operating Loss Carryforwards	$216.01M-3.0%	$222.74M—	——	——
R&D credit carryforward	$63.46M+1.8%	$62.31M—	——	——
Deferred Tax Assets, Valuation Allowance	$46.7M-85.8%	$329.23M—	——	——
Deferred Tax Liabilities, Other	$327K+436%	$61K—	——	——
Cost not yet recognized	$14.7M—	——	——	——
Thereafter	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$5.61M+72.1%	$3.26M—	——	——
2028	$2.35M—	——	——	——
2030	$2.35M—	——	——	——
2031	$2.35M—	——	——	——
Remainder of 2026	——	——	——	——
2027	$2.35M—	——	——	——
2029	$2.35M—	——	——	——
Finite Lived Intangible Assets Amortization Expense After Year Five	$12.99M—	——	——	——
Gross Carrying Amount	$30.36M0.0%	$30.36M—	——	——
Interest receivable on interest rate and cross currency swaps	$900K—	——	——	——
Inventory And Inventory Reported As Other Assets	$13.14M+79.5%	$7.32M—	——	——
Raw materials	$4.51M+319%	$1.08M—	——	——
Other assets	$1.63M+24.0%	$1.32M—	——	——
Investments Fair Value Disclosure	$134.94M+136%	$57.19M—	——	——
Lessee Operating Lease Liability Payments Due	$1.1M—	——	——	——
Loans Payable	$52.29M-12.4%	$59.68M—	——	——
2028	$22.5M—	——	——	——
2027	$30M—	——	——	——
Remainder of 2026	——	——	——	——
Loans Payable, Noncurrent	$22.48M-57.1%	$52.41M+0.1%	$52.37M+32.8%	$39.45M+98.1%
Contractual obligations due within two to three years, not included in financial statements	$9.7M—	——	——	——
Contractual obligations not included in financial statements	$21.5M—	——	——	——
Other accrued liabilities	$11.47M-2.4%	$11.75M+120%	$5.33M-17.7%	$6.49M+35.8%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$0—	——	——
Preferred Stock, Shares Authorized	$10M0.0%	$10M—	——	——
Preferred Stock, Shares Issued	$0—	$0—	——	——
Preferred Stock, Shares Outstanding	$0—	$0—	——	——
Prepaid inventory	$11.85M+215%	$3.76M—	——	——
Prepaid research and development costs	$4.89M+159%	$1.89M—	——	——
Prepaid research and development costs	$4.89M—	——	——	——
Incentive stock program, shares reserved for future grants (in shares)	——	——	——	——
Unrecognized tax benefits	$9.05M+3.1%	$8.78M+1.2%	$8.67M-8.0%	$9.43M—
Penalties and interest accrued on unrecognized tax benefits	$0—	——	——	——
Valuation Allowances And Reserves Balance	$27.72M+4.8%	$26.44M+68.6%	$15.68M—	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Rigel Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Rigel Pharmaceuticals's total assets?: Rigel Pharmaceuticals (RIGL) holds $504.6M in total assets, up 186.8% year over year.
How much debt does Rigel Pharmaceuticals have?: Rigel Pharmaceuticals carries $68.4M in total debt against $399.9M of shareholders' equity, a debt-to-equity ratio of 0.17.
How much cash does Rigel Pharmaceuticals have?: Rigel Pharmaceuticals holds $24.5M in cash and equivalents.
Can Rigel Pharmaceuticals cover its short-term obligations?: Its current ratio is 2.62 — current assets exceed current liabilities.
Where does Rigel Pharmaceuticals's balance sheet data come from?: Every line is extracted from Rigel Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.